Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/10591
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Data de embargo
2016-02-29
Coleções
Metadata
Mostrar registro completo
MECHANISM OF MULTIVALENT NANOPARTICLE ENCOUNTER WITH HIV-1 FOR POTENCY ENHANCEMENT OF PEPTIDE TRIAZOLE VIRUS INACTIVATION.
Proteína gp120 do Envelope de HIV/antagonistas & inibidores
HIV-1/efeitos de drogas
Nanoconjugados/toxicidade
Peptídeos/farmacologia
Triazóis/farmacologia
Fármacos Anti-HIV/síntese química
Linhagem Celular Tumoral
Relação Dose-Resposta a Droga
Ouro/química
Proteína gp120 do Envelope de HIV/química
HIV-1/crescimento & desenvolvimento
Humanos
Nanoconjugados/ultraestrutura
Tamanho da Partícula
Peptídeos/síntese química
Ligação Proteica
Triazóis/síntese química
Inativação de Vírus/efeitos de drogas
Internalização do Vírus/efeitos de drogas
Autor(es)
Afiliação
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Drexel University. Department of Chemical and Biological Engineering. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University. Department of Chemical and Biological Engineering. Philadelphia, Pennsylvania
Jefferson University. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania / Drexel University. School of Biomedical Engineering. Science and Health Systems. Philadelphia, Pennsylvania
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Drexel University. Department of Chemical and Biological Engineering. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University. Department of Chemical and Biological Engineering. Philadelphia, Pennsylvania
Jefferson University. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Drexel University College of Medicine. Department of Biochemistry and Molecular Biology. Philadelphia, Pennsylvania
Resumo em Inglês
Entry of HIV-1 into host cells remains a compelling yet elusive target for developing agents to prevent infection. A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis. We found that gold nanoparticle-conjugated forms of peptide triazoles (AuNP-PT) exhibit substantially more potent antiviral effects against HIV-1 than corresponding peptide triazoles alone. Here, we sought to reveal the mechanism of potency enhancement underlying nanoparticle conjugate function. We found that altering the physical properties of the nanoparticle conjugate, by increasing the AuNP diameter and/or the density of PT conjugated on the AuNP surface, enhanced potency of infection inhibition to impressive picomolar levels. Further, compared with unconjugated PT, AuNP-PT was less susceptible to reduction of antiviral potency when the density of PT-competent Env spikes on the virus was reduced by incorporating a peptide-resistant mutant gp120. We conclude that potency enhancement of virolytic activity and corresponding irreversible HIV-1 inactivation of PTs upon AuNP conjugation derives from multivalent contact between the nanoconjugates and metastable Env spikes on the HIV-1 virus. The findings reveal that multispike engagement can exploit the metastability built into virus the envelope to irreversibly inactivate HIV-1 and provide a conceptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively for metastable enveloped viruses generally
DeCS
Fármacos Anti-HIV/farmacologiaProteína gp120 do Envelope de HIV/antagonistas & inibidores
HIV-1/efeitos de drogas
Nanoconjugados/toxicidade
Peptídeos/farmacologia
Triazóis/farmacologia
Fármacos Anti-HIV/síntese química
Linhagem Celular Tumoral
Relação Dose-Resposta a Droga
Ouro/química
Proteína gp120 do Envelope de HIV/química
HIV-1/crescimento & desenvolvimento
Humanos
Nanoconjugados/ultraestrutura
Tamanho da Partícula
Peptídeos/síntese química
Ligação Proteica
Triazóis/síntese química
Inativação de Vírus/efeitos de drogas
Internalização do Vírus/efeitos de drogas
Compartilhar